Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data
April 3, 2016 11:45 AM EDT
CHICAGO, April 3, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke. The results of the... More
April 2, 2016 9:00 AM EDT
CHICAGO, April 2, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully achieved its primary endpoint at two years. The results of the study were presented as part of the late-breaking clinical trials at the American College of Cardiology's 65th Annual Scientific Session (ACC.16) in Chicago, and simultaneously published online in The New England Journal of... More
